Article Text

Download PDFPDF
After the smoke has cleared: evaluation of the impact of a new national smoke-free law in New Zealand
  1. R Edwards1,
  2. G Thomson1,
  3. N Wilson1,
  4. A Waa6,
  5. C Bullen2,
  6. D O’Dea1,
  7. H Gifford3,
  8. M Glover4,
  9. M Laugesen5,
  10. A Woodward7
  1. 1
    Department of Public Health, University of Otago, Wellington, New Zealand
  2. 2
    Clinical Trials Research Unit, School of Population Health, University of Auckland, Auckland, New Zealand
  3. 3
    Whakauae Research Services, Whanganui, New Zealand
  4. 4
    Auckland Tobacco Control Research Centre, School of Population Health, University of Auckland, Auckland, New Zealand
  5. 5
    Health New Zealand Ltd, Christchurch. New Zealand
  6. 6
    Health Sponsorship Council Research and Evaluation Unit, Wellington, New Zealand
  7. 7
    School of Population Health, University of Auckland, Auckland, New Zealand
  1. Dr Richard Edwards, Department of Public Health, University of Otago, Wellington, New Zealand; Richard.Edwards{at}otago.ac.nz

Footnotes

  • Funding: The evaluation and some of the primary data collection were funded by the New Zealand Ministry of Health. Other primary research studies were funded by a variety of agencies detailed in the relevant publications. The views expressed are those of the authors and do not necessarily represent those of the Ministry of Health.

  • Competing interests: GT, NW, MG, DO’D and ML have previously undertaken contract work for not for profit organisations involved in tobacco control. MG is on the advisory board for Pfizer Champix, and has been on similar boards for GSK Zyban in the past, and carried out contract work for Novartis training Aukati Kai Paipa in use of NRT many years ago.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding: The evaluation and some of the primary data collection were funded by the New Zealand Ministry of Health. Other primary research studies were funded by a variety of agencies detailed in the relevant publications. The views expressed are those of the authors and do not necessarily represent those of the Ministry of Health.

  • Competing interests: GT, NW, MG, DO’D and ML have previously undertaken contract work for not for profit organisations involved in tobacco control. MG is on the advisory board for Pfizer Champix, and has been on similar boards for GSK Zyban in the past, and carried out contract work for Novartis training Aukati Kai Paipa in use of NRT many years ago.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.